IN THE CLAIMS:

Please amend the claims as follows:

1. (CANCELLED)

2. (CURRENTLY AMENDED) A therapeutic agent delivery implant for implantation into a patient's body, said implant consisting essentially of:

a resilient or flexible, at least partially hydrophobic reticulated elastomeric support foam matrix scaffold formed from a polyurethane polymer or pre-polymer; and

a hydrophilic coating arranged on said scaffold,

wherein said coating contains one or more therapeutic agents for release within the patient.

3. (PREVIOUSLY PRESENTED) The implant of Claim 2, wherein the scaffold comprises at least one therapeutic agent.

4. (CURRENTLY AMENDED) The implant of Claim 2, wherein at least one of the one or more therapeutic ~~agent~~ agents is contained within microspheres in the coating.

5. (PREVIOUSLY PRESENTED) The implant of Claim 2, wherein the scaffold is biodurable.

6. (ORIGINAL) The implant of Claim 2, wherein at least one therapeutic agent is contained within microspheres in the coating.

7. (ORIGINAL) The implant of Claim 2, wherein the coating contains enzymes.

8. (PREVIOUSLY PRESENTED) The implant of Claim 2, wherein the scaffold comprises a hydrophobic polyurethane.

9. (ORIGINAL) The implant of Claim 2, wherein the coating comprises a hydrophilic polyurethane.

10. (PREVIOUSLY PRESENTED) The implant of Claim 2, wherein the therapeutic agent is selected from the group consisting of a pharmaceutical, a growth factor, an enzyme, RNA, DNA, a nucleic acid, and a vector, and mixtures of two or more thereof.

11. (PREVIOUSLY PRESENTED) The implant of Claim 2 which has a hemispherical, bullet, football, cylindrical, spherical, or irregular shape.

12. (ORIGINAL) The implant of Claim 11 which is spaghetti-shaped.

13 to 60. (CANCELLED)

61. (PREVIOUSLY PRESENTED) The implant of Claim 2, wherein the scaffold comprises a biodurable, resilient, compressible, elastomeric reticulated matrix.

62. (CANCELLED)

63. (PREVIOUSLY PRESENTED) The implant of Claim 2, wherein the scaffold can be compressed during delivery and can recover to a working size and configuration *in situ* at the implantation site.

64. (PREVIOUSLY PRESENTED) The implant of Claim 9 which after recovery to a working size and configuration is similar to a size and shape before compression.

65. (PREVIOUSLY PRESENTED) The implant of Claim 9 which can be retrieved and withdrawn from the patient's body.

66. (PREVIOUSLY PRESENTED) The reticulated implant of Claim 2 which allows for substantial fluid permeability, good flow through characteristics and access for body fluid to the drug bearing surfaces.

67. (PREVIOUSLY PRESENTED) The reticulated implant of Claim 2 which facilitates transport of therapeutic agent or that is secured to and/or supported by the scaffold.

68. (PREVIOUSLY PRESENTED) The implant of claim 2, wherein the scaffold material is selected from the group consisting of polycarbonate polyurethane.

69. (PREVIOUSLY PRESENTED) The implant of claim 2, wherein the scaffold material is selected from the group consisting of polycarbonate polyurethane, or polycarbonate-polysiloxane polyurethanes, polysiloxane polyurethanes, polycarbonate-hydrocarbon polyurethanes, polycarbonate-hydrocarbon polyurethane-ureas, and mixtures of two or more thereof.

70 - 71. (CANCELLED)

72. (PREVIOUSLY PRESENTED) The implant of Claim 2, wherein the coating comprises a foam.

73. (PREVIOUSLY PRESENTED) The implant of Claim 2, wherein the coating comprises a film.

74. (PREVIOUSLY PRESENTED) The implant of Claim 2, wherein the coating comprises a hydrogel.

75. (PREVIOUSLY PRESENTED) The implant of Claim 2, wherein the coating comprises a biodegradable polymer.

76. (PREVIOUSLY PRESENTED) The implant of Claim 2, wherein the coating comprises a non-biodegradable polymer.

77. (CANCELLED)

78. (CANCELLED)

79. (PREVIOUSLY PRESENTED) The implant of Claim 2, wherein the foam matrix scaffold comprises interconnected pores and the average diameter or other largest transverse dimension of the pores is from about 50 μm to about 2000 μm.

80. (PREVIOUSLY PRESENTED) The implant of Claim 79, wherein the average diameter or other largest transverse dimension of the pores is from about 50 μm to about 800 μm.

81. (PREVIOUSLY PRESENTED) The implant of Claim 80, wherein the average diameter or other largest transverse dimension of the pores is from about 100 μm to about 500 μm.

82. (PREVIOUSLY PRESENTED) The implant of Claim 2, wherein the void phase of the foam matrix scaffold is at least 50% by volume of the volume of the scaffold.

83. (PREVIOUSLY PRESENTED) The implant of Claim 81, wherein the void phase of the foam matrix scaffold is from about 70% to about 99% of the volume of the scaffold.